Ultragenyx Pharmaceutical (FRA:UP0) ROCE % : -35.60% (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Ultragenyx Pharmaceutical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ultragenyx Pharmaceutical's annualized ROCE % for the quarter that ended in Sep. 2024 was -35.60%.

Ultragenyx Pharmaceutical ROCE % Historical Data

The historical data trend for Ultragenyx Pharmaceutical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical ROCE % Chart

Ultragenyx Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-47.93

-11.26

-30.26

-51.84

-42.84

Ultragenyx Pharmaceutical Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-55.56	-39.55	-54.45	-38.31	-35.60

Ultragenyx Pharmaceutical ROCE % Calculation

Ultragenyx Pharmaceutical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-497.436	/	( ( (1458.899 - 246.582)	+	(1367.259 - 257.161) )	/ 2 )
	=	-497.436	/	( (1212.317	+	1110.098)	/ 2 )
	=	-497.436	/	1161.2075
	=	-42.84 %

Ultragenyx Pharmaceutical's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-423.472	/	( ( (1503.528 - 253.493)	+	(1386.065 - 256.792) )	/ 2 )
	=	-423.472	/	( ( 1250.035	+	1129.273 )	/ 2 )
	=	-423.472	/	1189.654
	=	-35.60 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Ultragenyx Pharmaceutical (FRA:UP0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ultragenyx Pharmaceutical ROCE % Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultragenyx Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (FRA:UP0) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RARE:USA RARE:Mexico 0LIF:UK UP0:Germany

Address

60 Leveroni Court, Novato, CA, USA, 94949

Website

https://www.ultragenyx.com

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical Headlines

No Headlines